The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1751
ISSUE1751
March 30, 2026
Drugs for Dementia
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Drugs for Dementia
March 30, 2026 (Issue: 1751)
Alzheimer's disease (AD) is the most common cause
of dementia, but cognitive decline also occurs in
other neurological conditions, such as Parkinson's
disease, Lewy body dementia, vascular dementia, and
frontotemporal dementia.
- NI Bradfield. Mild cognitive impairment: diagnosis and subtypes. Clin EEG Neurosci 2023; 54:4. doi:10.1177/15500594211042708
- G Marucci et al. Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease. Neuropharmacology 2021; 190:108352. doi:10.1016/j.neuropharm.2020.108352
- TC Russ and JR Morling. Cholinesterase inhibitors for mild cognitive impairment. Cochrane Database Syst Rev 2012; 9:CD009132. doi:10.1002/14651858.cd009132.pub2
- SE Black et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007; 69:459. doi:10.1212/01.wnl.0000266627.96040.5a
- B Winblad et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367:1057. doi:10.1016/s0140-6736(06)68350-5
- MR Farlow et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther 2010; 32:1234. doi:10.1016/j.clinthera.2010.06.019
- M Rolinski et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev 2012; 3:CD006504. doi:10.1002/14651858.cd006504.pub
- D Wilkinson et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003; 61:479. doi:10.1212/01.wnl.0000078943.50032.fc
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- Benzgalantamine (Zunveyl) for Alzheimer's disease. Med Lett Drugs Ther 2025; 67:59.
- K Rockwood et al. Attainment of treatment goals by people with Alzheimer's disease receiving galantamine: a randomized controlled trial. CMAJ 2006; 174:1099. doi:10.1503/cmaj.051432
- GK Wilcock et al. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ 2000; 321:1445. doi:10.1136/bmj.321.7274.1445
- PN Tariot et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54:2269. doi:10.1212/wnl.54.12.2269
- K Hager et al. Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease. Neuropsychiatr Dis Treat 2014; 10:391. doi:10.2147/ndt.s57909
- K Hager et al. Effect of concomitant use of memantine on mortality and efficacy outcomes of galantamine-treated patients with Alzheimer's disease: post-hoc analysis of a randomized placebo-controlled study. Alzheimers Res Ther 2016; 8:47. doi:10.1186/s13195-016-0214-x
- T Erkinjuntti et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359:1283. doi:10.1016/s0140-6736(02)08267-3
- R Bullock et al. Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine. Dement Geriatr Cogn Disord 2004; 17:29. doi:10.1159/000074140
- JS Birks et al. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2015; 9:CD001191. doi:10.1002/14651858. cd001191.pub4
- B Winblad et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007; 22:456. doi:10.1002/gps.1788
- MR Farlow et al. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia. CNS Neurosci Ther 2013; 19:745. doi:10.1111/cns.12158
- E Mamikonyan et al. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo-controlled study. Mov Disord 2015; 30:912. doi:10.1002/mds.26236
- I McKeith et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356:2031. doi:10.1016/s0140-6736(00)03399-7
- C Ballard et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr Med Res Opin 2008; 24:2561. doi:10.1185/03007990802328142
- H Xu et al. Long-term effects of cholinesterase inhibitors on cognitive decline and mortality. Neurology 2021; 96:e2220. doi:10.1212/wnl.0000000000011832
- PT Francis et al. Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease. Expert Rev Neurother 2012; 12:1351. doi:10.1586/ern.12.124
- R McShane et al. Memantine for dementia. Cochrane Database Syst Rev 2019; 3:CD003154. doi:10.1002/14651858.cd003154.pub6
- AP Porsteinsson et al. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008; 5:83. doi:10.2174/156720508783884576
- PN Tariot et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291:317. doi:10.1001/jama.291.3.317
- R Howard et al. Donepezil and memantine for moderate-to-severe Alzheimer’s disease. N Engl J Med 2012; 366:893. doi:10.1056/nejmoa1106668
- JM Orgogozo et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33:1834. doi:10.1161/01.str.0000020094.08790.49
- G Wilcock et al. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002; 17:297. doi:10.1097/00004850-200211000-00005
- HF Wang et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry 2015; 86:135. doi:10.1136/jnnp-2014-307659
- Lecanemab (Leqembi) granted full approval for early Alzheimer’s disease. Med Lett Drugs Ther 2023; 65:129.
- Donanemab (Kisunla) for Alzheimer’s disease. Med Lett Drugs Ther 2024; 66:129.
- JR Sims et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 2023; 330:512. doi:10.1001/jama.2023.13239
- CH van Dyck et al. Lecanemab in early Alzheimer's disease. N Engl J Med 2023; 388:9. doi:10.1056/nejmoa2212948
- J Cummings et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis 2023; 10:362. doi:10.14283/jpad.2023.30
- MW Dysken et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA 2014; 311:33. doi:10.1001/jama.2013.282834
- RJ Kryscio et al. Association of antioxidant supplement use and dementia in the prevention of Alzheimer’s disease by vitamin E and selenium trial (PREADViSE). JAMA Neurol 2017; 74:567. doi:10.1001/jamaneurol.2016.5778
- LS Schneider et al. A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer’s type. Curr Alzheimer Res 2005; 2:541. doi:10.2174/156720505774932287
- B Vellas et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer’s disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 2012; 11:851. doi:10.1016/s1474-4422(12)70206-5
- Apoaequorin (Prevagen) to improve memory. Med Lett Drugs Ther 2021; 63:175.
- VI Reus et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry 2016; 173:543. doi:10.1176/appi.ajp.2015.173501
- DL Sultzer et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry 2008; 165:844. doi:10.1176/appi.ajp.2008.07111779
- Brexpiprazole (Rexulti) for agitation in Alzheimer’s dementia. Med Lett Drugs Ther 2023; 65:99.
- CLP Vigen et al. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD. Am J Psychiatry 2011; 168:831. doi:10.1176/appi.ajp.2011.08121844
- PN Tariot et al. Trial of pimavanserin in dementia-related psychosis. N Engl J Med 2021; 385:309. doi:10.1056/nejmoa2034634
- DP Seitz et al. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev 2011; 2:CD008191. doi:10.1002/14651858.cd008191.pub2
- JL Cummings et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA 2015; 314:1242. doi:10.1001/jama.2015.10214
- A blood test for Alzheimer’s disease. Med Lett Drugs Ther 2025; 67:109.
- Elecsys – a second blood test for Alzheimer’s disease. Med Lett Drugs Ther 2026; 68:18.
- AD-Detect – a blood test for Alzheimer’s disease. Med Lett Drugs Ther 2023; 65:175.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Dementia
Article code: 1751a
Article code: 1751a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.